Sanofi (SNY) Stock Forecast & Price Target

$58.98 +0.07 (+0.11%)

As of 09:47 AM Eastern

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 4 Analyst Ratings

Sell
0

Hold
1

Buy
3

Based on 4 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 1 has given a hold rating, 1 has given a buy rating, and 2 have given a strong buy rating for SNY.

Consensus Price Target

$60.00
1.72% Upside

According to the 4 analysts' twelve-month price targets for Sanofi, the average price target is $60.00. The highest price target for SNY is $60.00, while the lowest price target for SNY is $60.00. The average price target represents a forecasted upside of 1.72% from the current price of $58.99.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 3/18/24 to 3/18/25	1 Month Ago 2/17/24 to 2/16/25	3 Months Ago 12/19/23 to 12/18/24	1 Year Ago 3/19/23 to 3/18/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$60.00	$60.00	$57.50	$57.50
Forecasted Upside	1.72% Upside	10.09% Upside	22.31% Upside	20.22% Upside
Consensus Rating	Buy	Buy	Buy	Hold

Remove Ads

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	3.25	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.83% Upside	22,155.10% Upside	18.07% Upside
News Sentiment Rating	Positive News See Recent SNY News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/30/2025	Sanford C. Bernstein 3 of 5 stars	F. Cespedes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/30/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Upgrade	Sell ➝ Hold
9/17/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$55.00	+8.20%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:48 AM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 12, 2025. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi's stock is currently priced at $59.25, reflecting a strong market position and potential for growth.
Recent upgrades from analysts, including a "strong-buy" rating from Sanford C. Bernstein, indicate positive sentiment and confidence in the company's future performance.
The company has seen significant institutional investment, with 14.04% of its stock owned by hedge funds and institutional investors, suggesting strong backing and confidence from major financial players.
Sanofi has a solid financial foundation, with a low debt-to-equity ratio of 0.15, indicating that the company is not overly reliant on debt to finance its operations, which can be a sign of financial health.
Recent trading volumes have been robust, with over 3.6 million shares traded recently, suggesting strong investor interest and liquidity in the stock.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Despite recent upgrades, some analysts have downgraded the stock from "buy" to "hold," indicating a cautious outlook that may suggest limited upside potential in the near term.
The stock has a relatively high P/E ratio of 23.80, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
Sanofi's recent price performance shows fluctuations, with a 52-week low of $45.22, which may raise concerns about volatility and risk for investors.
Institutional investors have also made significant cuts to their positions, such as Patten Group Inc. reducing its holdings by 27.8%, which could signal a lack of confidence in the stock's future performance.
Market conditions can be unpredictable, and any adverse developments in the pharmaceutical sector could negatively impact Sanofi's stock price and investor sentiment.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $60.00, with a high forecast of $60.00 and a low forecast of $60.00.
: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There is currently 1 hold rating, 1 buy rating and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 1.72% based on their 12-month stock forecasts.
: Over the previous 90 days, Sanofi's stock had 2 upgrades by analysts.
: Sanofi has been rated by research analysts at Deutsche Bank Aktiengesellschaft, and Sanford C. Bernstein in the past 90 days.
: Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SNY) was last updated on 3/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target